Supernus Pharmaceuticals (SUPN) Other Working Capital Changes (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Other Working Capital Changes data on file, last reported at $12.4 million in Q1 2026.

• Other Working Capital Changes for Q1 2026 came in at $12.4 million, up 268.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $33.0 million (up 639.03% YoY), and the FY2025 annual result was $13.2 million, down 31.9% from the prior year.
• Other Working Capital Changes rose to $12.4 million in Q1 2026 per SUPN's latest filing, from $6.9 million in the prior quarter.
• Over five years, Other Working Capital Changes peaked at $28.2 million in Q2 2023 and troughed at -$20.4 million in Q3 2023.
• A 5-year average of $1.9 million and a median of $341000.0 in 2023 frame the typical range for Other Working Capital Changes.
• On a YoY basis, Other Working Capital Changes climbed as much as 3603.48% in 2023 and fell as far as 1556.33% in 2023.
• A 5-year view of Other Working Capital Changes shows it stood at -$9.2 million in 2022, then grew by 15.22% to -$7.8 million in 2023, then jumped by 238.52% to $10.8 million in 2024, then sank by 36.12% to $6.9 million in 2025, then surged by 80.04% to $12.4 million in 2026.
• Business Quant data shows SUPN's Other Working Capital Changes at $12.4 million in Q1 2026, $6.9 million in Q4 2025, and $11.1 million in Q3 2025.